interferon alfa 2a

Summary

Summary: A recombinant alfa interferon consisting of 165 amino acids with lysine at position 23 and histidine at position 34. It is used extensively as an antiviral and antineoplastic agent.

Top Publications

  1. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
  2. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
  3. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
  4. ncbi Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
  5. ncbi Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
  6. ncbi Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
  7. ncbi Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet 370:2103-11. 2007
  8. ncbi A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
    K L Lindsay
    University of Southern California, Los Angeles, CA 90033, USA
    Hepatology 34:395-403. 2001
  9. ncbi Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
    Jian Wu Yu
    Department of Infectious Diseases, Second Affiliated Hospital, Harbin Medical University, Nangang District, Harbin, China
    J Gastroenterol Hepatol 22:832-6. 2007
  10. ncbi Predictors of response of US veterans to treatment for the hepatitis C virus
    Lisa I Backus
    Center for Quality Management in Public Health, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA
    Hepatology 46:37-47. 2007

Detail Information

Publications225 found, 100 shown here

  1. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
    ..In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin...
  2. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C...
  3. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  4. ncbi Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
    ..Strategies to maximize adherence are being developed and, in the future, may include early identification of and therapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic abnormalities...
  5. ncbi Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
    ....
  6. ncbi Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  7. ncbi Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet 370:2103-11. 2007
    ..Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa was warranted...
  8. ncbi A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
    K L Lindsay
    University of Southern California, Los Angeles, CA 90033, USA
    Hepatology 34:395-403. 2001
    ..The higher rate of virologic response during treatment with 1.5 microg/kg peginterferon alfa-2b in patients infected with genotype 1 and high viral levels warrants further evaluation...
  9. ncbi Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
    Jian Wu Yu
    Department of Infectious Diseases, Second Affiliated Hospital, Harbin Medical University, Nangang District, Harbin, China
    J Gastroenterol Hepatol 22:832-6. 2007
    ..The aim of this study was to investigate the predictive value of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) in HCV patients treated with peg-IFN-alpha-2a and ribavirin...
  10. ncbi Predictors of response of US veterans to treatment for the hepatitis C virus
    Lisa I Backus
    Center for Quality Management in Public Health, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA
    Hepatology 46:37-47. 2007
    ..For genotype 3 patients, only receiving PEG-INF 2A affected the likelihood of an SVR; its effect was positive...
  11. ncbi Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    Gastroenterology 127:1724-32. 2004
    ....
  12. ncbi Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
    W G E Cooksley
    Royal Brisbane Hospital, Herston, Queensland, Australia
    J Viral Hepat 10:298-305. 2003
    ..These results indicate that peginterferon alpha-2a (40 kDa) is superior in efficacy to conventional interferon alpha-2a in chronic hepatitis B based on clearance of HBeAg, suppression of HBV DNA, and normalization of ALT...
  13. ncbi Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance
    J Tilman Gerlach
    Medical Department II, Klinikum Grosshadern and Institute for Immunology, Schwabing, Munich, Germany
    Gastroenterology 125:80-8. 2003
    ..The aim of this study was to define the natural course of the disease and to contribute to the development of treatment strategies for acute hepatitis C virus...
  14. ncbi Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Gastroenterology 132:103-12. 2007
    ..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment...
  15. ncbi Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
    Jose M Sanchez-Tapias
    Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Gastroenterology 131:451-60. 2006
    ..This study investigated whether treatment for 72 weeks increases the rate of SVR in patients with detectable hepatitis C virus (HCV)-RNA levels at week 4 of treatment...
  16. doi Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    N Engl J Med 360:257-67. 2009
    ..We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously...
  17. ncbi Side effects of therapy for chronic hepatitis C
    Mark W Russo
    Division of Digestive Diseases, University of North Carolina at Chapel Hill, 27599, USA
    Gastroenterology 124:1711-9. 2003
  18. ncbi [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea]
    Hyuk Lee
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Korean J Hepatol 12:31-40. 2006
    ..We evaluated the efficacy and safety of administering peginterferon alfa-2a plus ribavirin in native Korean patients with chronic hepatitis C...
  19. ncbi Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
    J Atzpodien
    Medizinische Hochschule Hannover, Germany
    J Clin Oncol 22:1188-94. 2004
    ..We conducted a prospectively randomized clinical trial to compare the efficacy of three outpatient therapy regimens in 341 patients with progressive metastatic renal cell carcinoma...
  20. ncbi Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
    Hari S Conjeevaram
    Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 131:470-7. 2006
    ..Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy...
  21. ncbi Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
    Ana I Romero
    Department of Virology, University of Goteborg, Goteborg, Sweden
    J Infect Dis 194:895-903. 2006
    ..We investigated associations between interferon (IFN)-gamma-inducible protein (IP)-10 and liver histological results, viral kinetic response, and treatment outcome in patients infected with hepatitis C virus (HCV) genotypes 1-4...
  22. ncbi Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C
    K Rajender Reddy
    Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Adv Drug Deliv Rev 54:571-86. 2002
    ..Peginterferon alfa-2a (40 KD) has comparable safety to interferon alfa-2a. The addition of ribavirin to peginterferon alfa-2a (40 KD) further enhances the therapeutic benefit for patients with hepatitis C...
  23. ncbi Peginterferon alfa-2a in patients with chronic hepatitis C
    S Zeuzem
    Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    N Engl J Med 343:1666-72. 2000
    ..We compared the clinical effects of a regimen of peginterferon alfa-2a with those of a regimen of interferon alfa-2a in the initial treatment of patients with chronic hepatitis C...
  24. ncbi IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
    ..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention...
  25. ncbi Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Gastroenterology 123:1061-9. 2002
    ..We evaluated the impact of adherence to combination therapy with interferon or peginterferon plus ribavirin in chronic hepatitis C patients...
  26. pmc Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
    Eric Snoeck
    Exprimo NV, Lummen, Belgium, F Hoffmann La Roche Nutley, NJ, USA
    Br J Clin Pharmacol 62:699-709. 2006
    ..To assess the likelihood of a sustained virological response (SVR) vs. the likelihood of anaemia in patients with chronic hepatitis C...
  27. ncbi Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C
    A M Di Bisceglie
    Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO 63110, USA
    J Viral Hepat 14:721-9. 2007
    ....
  28. ncbi Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD)
    K Rajender Reddy
    Gastrointestinal Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Semin Liver Dis 24:33-8. 2004
    ..The much-increased sustained virological response rates observed with pegylated IFN alfa-2a (40 kD) and pegylated IFN alfa-2b (12 kD) support the rationale for pegylation of IFN...
  29. ncbi Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit
    Matthew W Wilson
    Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
    Ophthalmology 114:1007-11. 2007
    To report the use of a combination of low-dose cyclophosphamide and interferon alfa 2a (IFNalpha2a) for the treatment of orbital juvenile capillary hemangioma.
  30. ncbi Efficacy and tolerance of HCV treatment in HIV-HCV coinfected patients: the potential interaction of PI treatment
    I Poizot-Martin
    CISIH Sud, Département de Recherche Clinique RCCS, Hopital Sainte Marguerite, CHU de Marseille, France
    HIV Clin Trials 4:262-8. 2003
    ..To evaluate tolerance and efficacy of an open-label interferon-ribavirin treatment and their determinants in 62 HCV-HIV coinfected patients in routine followup...
  31. doi Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
    Bernard Escudier
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    J Clin Oncol 27:1280-9. 2009
    ....
  32. ncbi An unusual side effect of interferon alfa 2A: digital clubbing
    Mohammad Tanveer Alam
    Medical Unit V, Civil Hospital, Karachi, Pakistan
    J Ayub Med Coll Abbottabad 20:165-6. 2008
    ..No national or international data regarding such unusual side effect is available. Whether this effect is idiosyncratic or dose related and whether it is reversible or not after completion of treatment is yet to be established...
  33. ncbi Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481 and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 351:1206-17. 2004
    ..As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications...
  34. ncbi Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C
    K R Reddy
    University of Miami School of Medicine, Miami, FL, USA
    Hepatology 33:433-8. 2001
    ..The 180-microg PEG(40kd) IFN alpha-2a dose appeared to be the optimal dose based on sustained virological response and its associated side-effect profile...
  35. ncbi Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
    Francesca J Torriani
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, Antiviral Research Center, CA 92103, USA
    N Engl J Med 351:438-50. 2004
    ....
  36. ncbi Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    Donald M Jensen
    Center for Liver Diseasees, University of Chicago Hospitals, 60637, USA
    Hepatology 43:954-60. 2006
    ..In conclusion, patients infected with HCV genotype 1 and treated with peginterferon alpha-2a/ribavirin sustained a RVR 24% of the time. This portends an 89% probability of a SVR after 24 weeks of treatment...
  37. ncbi Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
    Manuel Romero-Gomez
    Hepatology Unit, Hospital Universitario de Valme, Sevilla, Spain
    Gastroenterology 128:636-41. 2005
    ..We evaluated the effect of insulin resistance and viral factors on sustained virological response in patients with chronic hepatitis C treated with peginterferon plus ribavirin...
  38. pmc Insulin resistance and hepatitis C
    Manuel Romero-Gomez
    Unit for The Clinical Management of Digestive Diseases Hospital Universitario de Valme Ctra de Cadiz s n Sevilla 41014, Spain
    World J Gastroenterol 12:7075-80. 2006
    ..In summary, hepatitis C promotes insulin resistance and insulin resistance induces interferon resistance, steatosis and fibrosis progression...
  39. pmc Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
    M Diago
    Section of Hepatology, University General Hospital, Valencia, Spain
    Gut 55:374-9. 2006
    ..Increased serum and intrahepatic interferon gamma inducible protein 10 (IP-10) levels in patients with chronic hepatitis C (CHC) have been described...
  40. ncbi Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
    Alessandra Mangia
    Gastroenterology, Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    Hepatology 47:43-50. 2008
    ..RVR patients with baseline viremia >or=400,000 IU/mL achieved higher SVR rates when treated for 48 weeks rather than 24 weeks (86.8% versus 73.1%, P = 0.14). The only predictive factor of SVR in RVR patients was advanced fibrosis...
  41. ncbi Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy
    Tsung Ming Chen
    Division of Hepato Gastroenterology, Department of Internal Medicine, Tungs Taichung Metroharbor Hospital, Taichung, Taiwan
    J Gastroenterol Hepatol 22:669-75. 2007
    ..The aim of this study was to investigate the predictors of elevated serum AFP in patients with CHC, and its change after Peg-IFN/RBV therapy...
  42. ncbi Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients
    Jose A Mira
    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 12:1225-35. 2007
    ..The objective of this study was to identify predictors of severe haematological toxicity among HIV-HCV-coinfected patients treated with PEG-IFN plus RBV...
  43. ncbi Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
    Thomas Berg
    Universitatsklinikum Charite, Campus Virchow Klinikum, Universitatsmedizin Berlin, Germany
    Gastroenterology 130:1086-97. 2006
    ..The extension of treatment duration beyond 48 weeks is one possible strategy to address this problem...
  44. ncbi Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC
    Nina Aass
    Department of Clinical Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    J Clin Oncol 23:4172-8. 2005
    ....
  45. ncbi Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
    Andrew J Muir
    Division of Gastroenterology, Duke University, Durham, NC, USA
    N Engl J Med 350:2265-71. 2004
    ..The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which has a lower response rate than other genotypes, has been suggested as the cause...
  46. pmc Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin
    Natalia Laufer
    Infectious Diseases Unit, Hospital Clinic, Barcelona, Spain
    Antivir Ther 13:953-7. 2008
    ..The aim of our study was to evaluate the effect of ABC on the response rate to HCV therapy...
  47. ncbi Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases...
  48. ncbi International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 43:250-7. 2005
    ..The aim of this study was to increase virologic response rates by individualized treatment according to the early virologic response...
  49. doi Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial
    Ming Lung Yu
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    Hepatology 47:1884-93. 2008
    ..6%), respectively. Multivariate analysis in all patients showed that RVR was the strongest independent factor associated with an SVR, followed by treatment duration, mean weight-based exposure of ribavirin, and baseline viral load...
  50. ncbi Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:429-37. 2008
    ..There is little information about the influence of antiretroviral drugs on the antiviral activity of pegylated interferon (PEG-IFN) plus ribavirin (RBV) against hepatitis C virus (HCV)...
  51. doi A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Hepatology 47:1816-23. 2008
    ..4%-83.7%) in group B. Relapse rates in the 2 treatment groups were similar (17% in group A and 20% in group B). The incidence of adverse events, laboratory abnormalities, and dose reductions was similar in the 2 treatment groups...
  52. ncbi Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Gastroenterology 135:451-8. 2008
    ....
  53. ncbi Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
    Mitchell L Shiffman
    Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    N Engl J Med 357:124-34. 2007
    ..We conducted a large, randomized, multinational, noninferiority trial to determine whether similar efficacy could be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin...
  54. ncbi High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C
    Karin Lindahl
    Department of Infectious Diseases, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden
    Hepatology 41:275-9. 2005
    ..In conclusion, a high dose of ribavirin according to an individualized schedule is feasible but associated with more frequent and serious side effects such as anemia. The viral response merits further evaluation...
  55. ncbi Peginterferon and ribavirin for chronic hepatitis C
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    N Engl J Med 355:2444-51. 2006
  56. doi Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
    J Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    J Antimicrob Chemother 63:1256-63. 2009
    ..We compared the effectiveness and safety of peg-IFN-alpha2a and peg-IFN-alpha2b, both with ribavirin, against chronic hepatitis C virus (HCV) infection in HIV-infected patients...
  57. ncbi Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C
    P Bailon
    Hoffmann La Roche Inc, Nutley, New Jersey 07110, USA
    Bioconjug Chem 12:195-202. 2001
    ..Results of Phase II/III hepatitis C clinical trials in humans confirmed the superior efficacy of pegylated interferon alpha-2a compared to unmodified interferon alpha-2a...
  58. ncbi Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies
    Thomas E Hutson
    Baylor University Medical Center, Sammons Cancer Center, Dallas, Texas 75246, USA
    Oncologist 13:1084-96. 2008
    ..Recognition and prompt management of side effects are important to avoid unnecessary dose reductions that may result in suboptimal efficacy...
  59. pmc Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy
    H Le Guillou-Guillemette
    Laboratory of Virology, Department of Infectious Agents, University Hospital of Angers, 4 rue Larrey, 49933 Angers Cedex 9, France
    World J Gastroenterol 13:2416-26. 2007
    ..Both mechanisms of the Interferon resistance and of the new antiviral drugs are described in this review...
  60. ncbi Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C
    Sanaa M Kamal
    Department of Internal Medicine II, Gastroenterology and Hepatology, University of Freiburg, Germany
    Gastroenterology 123:1070-83. 2002
    ..This study investigated if the greater efficacy of pegylated IFNs might be related to modulation of immunologic responses...
  61. ncbi Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
    Gastroenterology 126:1015-23; discussion 947. 2004
    ..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
  62. ncbi Future trends in managing hepatitis C
    John G McHutchison
    Division of Gastroenterology and GI Hepatology Research, Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27710, USA
    Gastroenterol Clin North Am 33:S51-61. 2004
    ..Multiple-drug regimens will likely be required to enhance viral clearance and reduce viral resistance, while providing greater tolerability...
  63. pmc Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection
    Thomas J Chambers
    Department of Molecular Microbiology and Immunology, St Louis University School of Medicine, St Louis University Health Sciences Center, St Louis, Missouri, USA
    J Virol 79:3071-83. 2005
    ..One interpretation of these data is that early viral responses are governed to some extent by viral factors, whereas sustained responses may be more influenced by host factors, in addition to effects of viral complexity and diversity...
  64. ncbi Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
    Lennox J Jeffers
    Miami Veterans Affairs Medical Center, Miami, FL, USA
    Hepatology 39:1702-8. 2004
    ....
  65. pmc Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy
    J M Pawlotsky
    Department of Bacteriology and Virology, Hopital Henri Mondor, Universite Paris XII, 94010 Creteil, France
    J Virol 73:6490-9. 1999
    ..These changes are associated with profound alterations of the natural outcome of HCV-related liver disease, raising the hypothesis of a causal relationship...
  66. ncbi Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons
    D Alvarez
    Drexel University College of Medicine, Philadelphia, PA, USA
    J Viral Hepat 13:683-9. 2006
    ..However, ZDV use was not associated with higher rates of treatment discontinuation or lower early virologic response rates. HIV and hepatitis C care providers should be cognizant of these data...
  67. ncbi Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Cleve Clin J Med 71:S17-21. 2004
    ..The impact of growth factors on sustained virologic response and their cost-effectiveness in patients with chronic hepatitis C need further assessment...
  68. doi Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27514, USA
    Hepatology 48:1033-43. 2008
    ..The arm with the higher doses of both drugs was less well-tolerated than the other regimens...
  69. pmc Diagnosis and treatment of chronic hepatitis C infection
    Keyur Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27707, USA
    BMJ 332:1013-7. 2006
  70. ncbi Expression modes of interferon-alpha inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-alpha
    Ulrich Certa
    Roche Center for Medical Genomics, F Hoffmann La Roche, Ltd, Postfach, Building 93 610, CH 4070 Basel, Switzerland
    Gene 315:79-86. 2003
    ..Finally, we propose that the ISRGs are activated downstream of the primary response genes by a molecule or pathway, which awaits identification, and interferon inducible gene expression is thus more complicated than previously thought...
  71. doi Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
    Karen L Lindsay
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Gastroenterol Hepatol 6:234-41. 2008
    ..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
  72. ncbi Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Hepatology 37:600-9. 2003
    ..This algorithm recognizes 53.7% of nonresponders previously identified at week 24 of treatment...
  73. ncbi Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C
    C M Perry
    Adis International Limited, Auckland, New Zealand
    Drugs 61:2263-88. 2001
    ..Headache, fatigue and myalgia are among the most common adverse events...
  74. ncbi Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Samuel S Lee
    Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
    J Hepatol 37:500-6. 2002
    ..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)...
  75. pmc Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome
    Patrizia Farci
    Department of Medical Sciences, University of Cagliari, 09124 Cagliari, Italy
    Proc Natl Acad Sci U S A 99:3081-6. 2002
    ....
  76. ncbi Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a
    Matthew W Lamb
    Department of Clinical Science, Hoffmann LaRoche Inc, 340 Kingsland Street, Nutley, NJ 07110 1199, USA
    Ann Pharmacother 36:933-5. 2002
  77. ncbi Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA 30309, USA
    Hepatology 46:1688-94. 2007
    ..Overall, the rate of SVR was superior in patients treated for 72 weeks versus 48 weeks (38% versus 18%, respectively; P = 0.026)...
  78. ncbi Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial
    Sylvie Negrier
    Universite de Lyon, Department of Medical Oncology and Cytokines and Cancer Research Unit, Leon Berard Center, INSERM U590, Lyon, France
    Cancer 110:2468-77. 2007
    ..The Programme Etude Rein Cytokines (PERCY) Quattro trial was designed to evaluate both cytokines for their survival benefit to intermediate prognosis patients, who represent the majority of candidates for these treatments...
  79. ncbi Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection
    Abdurrahman Sagir
    Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinik Düsseldorf, Dusseldorf, Germany
    Liver Int 27:954-9. 2007
    ..In this report, we investigated response rates to combination therapy [standard IFN-alpha or PEG-IFN-alpha and ribavirin] in patients who relapsed or failed in prior therapy...
  80. ncbi Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Antimicrob Chemother 53:15-8. 2004
    ..Patients who become HCV-RNA negative after 4 weeks have the best chance of achieving an SVR. The rapidity of viral elimination may be a useful guide to tailoring the length of treatment in patients with an EVR...
  81. ncbi Pegylated interferons for chronic hepatitis B
    Antonio Craxi
    Divisione di Gastroenterologia, Instituto di Clinica Medica Policlinico, University di Palermo, Piazzale Delle Cliniche 2, 90127 Palermo, Italy
    Antiviral Res 60:87-9. 2003
    ..In conclusion, peginterferon alpha-2a (40 kDa) is a promising emerging therapy for CHB...
  82. ncbi Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a
    S Zeuzem
    Medizinische Klinik II, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    Gastroenterology 120:1438-47. 2001
    ..The aim of the study was to compare viral kinetics in patients treated with standard or peginterferon alpha2a...
  83. ncbi Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study
    Christa Wenger
    Gastroenterology and Hepatology, University Hospital Zurich, Switzerland
    Swiss Med Wkly 137:418-23. 2007
    ..Our aim was to compare efficacy and tolerability of an interferon-alfa-2a (INF), ribavirin (RIBA) and amantadine (AMA) combination with those of an INF and RIBA combination...
  84. ncbi Response-guided therapy: optimizing treatment now and in the future
    Patrick Marcellin
    Antivir Ther 13:1-2. 2008
  85. ncbi [Therapy of chronic Hepatitis C in 2008]
    C Niederau
    Kath Kliniken Oberhausen gGmbH, Klinik fur Innere Medizin, St Josef Hospital Oberhausen, Oberhausen
    MMW Fortschr Med 150:31-4. 2008
  86. ncbi Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b
    Gaetano Scotto
    Clinic of Infectious Diseases, University of Foggia, Foggia, Italy
    Drugs 68:791-801. 2008
    ....
  87. ncbi Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study
    Amparo Escudero
    Service of Hepatology, University Hospital Clinic, Department of Medicine, University of Valencia, Valencia, Spain
    J Gastroenterol Hepatol 23:861-6. 2008
    ....
  88. ncbi Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
    Thomas Berg
    Charite Universitatsmedizin Berlin, Berlin, Germany
    Antivir Ther 13:17-22. 2008
    ..As in genotype 1 and 4 patients, response-guided therapy aims to optimize treatment outcomes for individuals, without compromising SVR rates...
  89. ncbi Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection
    Wolfgang Jessner
    Department of Internal Medicine III, Gastroenterology and Hepatology, Vienna Medical University, Vienna, Austria
    Antivir Ther 13:581-9. 2008
    ..Our aim was to investigate this approach in genotype 4 patients...
  90. ncbi Management of patients with chronic hepatitis C infection
    S K Herrine
    Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Exp Med 6:20-6. 2006
    ..As intravenous drug use remains the most important source of HCV transmission in the US and Europe, education within this group is an important preventive tool...
  91. ncbi Hepatitis C virus therapy to date
    Graham Foster
    Queen Mary Hospital, University of London, London, UK
    Antivir Ther 13:3-8. 2008
    ....
  92. ncbi A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Dusseldorf, Germany
    Hepatology 40:120-4. 2004
    ..Patients discontinuing therapy due to noncompliance or request did so early, thereby limiting the cost of an unsuccessful approach to treatment...
  93. ncbi Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*
    V Gonzalez
    Department of Microbiology, Hospital Germans Trias i Pujol, Badalona, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Viral Hepat 12:481-7. 2005
    ..6 and 75% respectively. HCV core antigen detection is quick, and easy to perform alternative to HCV RNA, and could be used as a marker of HCV viraemia for monitoring the progress of therapy...
  94. ncbi Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin
    D Carriero
    Division of Liver Diseases, Mount Sinai Medical Center and School of Medicine, New York City, USA
    Int J Artif Organs 31:295-302. 2008
    ..No safe and effective therapy exists for chronic hepatitis C in dialysis patients. Available data on the antiviral treatment of hepatitis C in dialysis population is mostly based on standard interferon monotherapy...
  95. ncbi A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)
    Marcelo Silva
    Hospital Universitario Austral, Pilar, Argentina
    J Hepatol 45:204-13. 2006
    ..To compare the pharmacokinetics, pharmacodynamics, and antiviral activity of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C virus genotype 1...
  96. ncbi Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy
    J Koirala
    Division of Infectious Diseases, Department of Medicine, School of Medicine, Southern Illinois University, Springfield, IL 62794 9636, USA
    J Viral Hepat 14:782-7. 2007
    ..Timing of G-CSF administration did not make any significant impact on the patient's neutrophil counts but was better tolerated when given 2 days apart from PEG-IFN-alpha...
  97. ncbi Short-duration therapy for hepatitis C: suitable for all?
    A Mangia
    Division of Gastroenterology, Hospital Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    J Viral Hepat 14:221-7. 2007
    ..However, some issues on this topic, are still open. In this review, existing evidence is discussed, and both the relevance and limitations of published studies are considered...
  98. doi Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    J Antimicrob Chemother 62:793-6. 2008
    ..However, data available on the efficacy of this therapy in co-infected patients who failed a former interferon-based regimen are limited...
  99. ncbi [Toxicity of the treatment of chronic hepatitis C with peginterferon alpha (2a or 2b) plus ribavirin in patients not previously treated]
    Juan Francisco Márquez Peiró
    Servicio de Farmacia, Hospital Universitario Dr Peset, Valencia, Espana
    Med Clin (Barc) 129:612-4. 2007
    ..The aims of this study are to determine the ADR that the patients have presented according to the type of peginterferon alpha, and the effect of these in treatment duration and accumulated dose...
  100. ncbi Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers
    H Senturk
    Department Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
    Neth J Med 66:191-5. 2008
    ..We aimed to evaluate the response rate and side effects of conventional or pegylated interferon combined with ribavirin on chronic HBV/HCV coinfection therapy...
  101. ncbi Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin
    M G Antonini
    Dept of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Infection 36:250-5. 2008
    ..Combination therapy with pegylated interferon (peginterferon) plus ribavirin is associated with several side effects, including neutropenia and infection...

Research Grants112 found, 100 shown here

  1. SUBMACULAR SURGERY TRIALS--PHOTOGRAPH READING CENTER
    Susan Bressler; Fiscal Year: 2003
    ..BUDGET NOTE: NEI Staff should evaluate the requested budget in light of their experience with the budget needs of reading centers in other clinical trials. ADMINISTRATIVE NOTE: Awards, if made, are limited to 5 years. ..
  2. SUBMACULAR SURGERY TRIALS--PHOTOGRAPH READING CENTER
    Susan Bressler; Fiscal Year: 2000
    ..BUDGET NOTE: NEI Staff should evaluate the requested budget in light of their experience with the budget needs of reading centers in other clinical trials. ADMINISTRATIVE NOTE: Awards, if made, are limited to 5 years. ..
  3. SUBMACULAR SURGERY TRIALS--PHOTOGRAPH READING CENTER
    Susan Bressler; Fiscal Year: 2000
    ..BUDGET NOTE: NEI Staff should evaluate the requested budget in light of their experience with the budget needs of reading centers in other clinical trials. ADMINISTRATIVE NOTE: Awards, if made, are limited to 5 years. ..
  4. SUBMACULAR SURGERY TRIALS--PHOTOGRAPH READING CENTER
    Susan Bressler; Fiscal Year: 2002
    ..BUDGET NOTE: NEI Staff should evaluate the requested budget in light of their experience with the budget needs of reading centers in other clinical trials. ADMINISTRATIVE NOTE: Awards, if made, are limited to 5 years. ..
  5. SUBMACULAR SURGERY TRIALS--PHOTOGRAPH READING CENTER
    Susan Bressler; Fiscal Year: 2001
    ..BUDGET NOTE: NEI Staff should evaluate the requested budget in light of their experience with the budget needs of reading centers in other clinical trials. ADMINISTRATIVE NOTE: Awards, if made, are limited to 5 years. ..
  6. SUBMACULAR SURGERY TRIALS--PHOTOGRAPH READING CENTER
    Susan Bressler; Fiscal Year: 1999
    ..BUDGET NOTE: NEI Staff should evaluate the requested budget in light of their experience with the budget needs of reading centers in other clinical trials. ADMINISTRATIVE NOTE: Awards, if made, are limited to 5 years. ..
  7. PEB IFN AND RIBAVIRIN VERSUS REBETRON IN HEPATITIS C
    Robert Brown; Fiscal Year: 2000
    ..At weeks 52, 60, and 72 study patients are expected to have laboratory tests; at week 68, only blood samples will need to be drawn ..
  8. HCV TREATMENT IN AFRICAN AMERICANS VS NON HISPANIC WHIT*
    Lennox Jeffers; Fiscal Year: 2004
    ..SPECIFIC AIM 7. To identify sociodemographic (e.g., age, education income, gender, ethnicity) and psychosocial (e.g., anxiety, depression, coping) predictors of adherence to treatment and virologic response to HCV RNA. ..
  9. HCV TREATMENT IN AFRICAN AMERICANS VS NON HISPANIC WHIT*
    Lennox Jeffers; Fiscal Year: 2001
    ..SPECIFIC AIM 7. To identify sociodemographic (e.g., age, education income, gender, ethnicity) and psychosocial (e.g., anxiety, depression, coping) predictors of adherence to treatment and virologic response to HCV RNA. ..
  10. HCV TREATMENT IN AFRICAN AMERICANS VS NON HISPANIC WHIT*
    Lennox Jeffers; Fiscal Year: 2004
    ..SPECIFIC AIM 7. To identify sociodemographic (e.g., age, education income, gender, ethnicity) and psychosocial (e.g., anxiety, depression, coping) predictors of adherence to treatment and virologic response to HCV RNA. ..
  11. HCV TREATMENT IN AFRICAN AMERICANS VS NON HISPANIC WHIT*
    Lennox Jeffers; Fiscal Year: 2002
    ..SPECIFIC AIM 7. To identify sociodemographic (e.g., age, education income, gender, ethnicity) and psychosocial (e.g., anxiety, depression, coping) predictors of adherence to treatment and virologic response to HCV RNA. ..
  12. HCV TREATMENT IN AFRICAN AMERICANS VS NON HISPANIC WHIT*
    Lennox Jeffers; Fiscal Year: 2005
    ..SPECIFIC AIM 7. To identify sociodemographic (e.g., age, education income, gender, ethnicity) and psychosocial (e.g., anxiety, depression, coping) predictors of adherence to treatment and virologic response to HCV RNA. ..
  13. HCV TREATMENT IN AFRICAN AMERICANS VS NON HISPANIC WHIT*
    Lennox Jeffers; Fiscal Year: 2003
    ..SPECIFIC AIM 7. To identify sociodemographic (e.g., age, education income, gender, ethnicity) and psychosocial (e.g., anxiety, depression, coping) predictors of adherence to treatment and virologic response to HCV RNA. ..
  14. Non-toxic Human Interferon-Alpha Analog
    Lorelie Villarete; Fiscal Year: 2004
    ..If this project is successful, it should be possible to administer NLVgalpha2b to patients in higher doses than can be achieved with current IFNalpha's, resulting in improved clinical outcomes. ..
  15. Non-toxic Human Interferon-Alpha Analog
    Lorelie Villarete; Fiscal Year: 2003
    ..If this project is successful, it should be possible to administer NLVgalpha2b to patients in higher doses than can be achieved with current IFNalpha's, resulting in improved clinical outcomes. ..
  16. Directly Observed Hepatitis C Treatment in Methadone Clinics
    ALAIN LITWIN; Fiscal Year: 2010
    ..Findings from this project will be used to inform the development of a large randomized trial of the efficacy and cost-effectiveness of modified directly observed HCV care versus regular on-site care. ..
  17. Directly Observed Hepatitis C Treatment in Methadone Clinics
    ALAIN LITWIN; Fiscal Year: 2009
    ..Findings from this project will be used to inform the development of a large randomized trial of the efficacy and cost-effectiveness of modified directly observed HCV care versus regular on-site care. ..
  18. PEGYLATED-IFN COMPARED TO STANDARD REGIMAN OF ROFERON -A FOR HEPATITIS C
    Luis Marsano; Fiscal Year: 2001
    ..abstract_text> ..
  19. PEG-IFN VS ROFERON A IN NONCIRRHOTIC HEPATITIS C
    Paul Pockros; Fiscal Year: 1999
    ..Endpoints for evaluation of efficacy will be normalization of ALT and disappearance of detectable HCV RNA from the serum. ..
  20. PEGYLATED-IFN COMPARED TO STANDARD REGIMAN OF ROFERON -A FOR HEPATITIS C
    Luis Marsano; Fiscal Year: 1999
    ..abstract_text> ..
  21. PEG IFN VS ROFERON A FOR CHRONIC HEPATITIS C WITH CIRRHOSIS
    Paul Pockros; Fiscal Year: 2000
    ..abstract_text> ..
  22. PEG-IFN VS ROFERON A IN NONCIRRHOTIC HEPATITIS C
    Paul Pockros; Fiscal Year: 2000
    ..Endpoints for evaluation of efficacy will be normalization of ALT and disappearance of detectable HCV RNA from the serum. ..
  23. PEGYLATED-IFN COMPARED TO STANDARD REGIMAN OF ROFERON -A FOR HEPATITIS C
    Luis Marsano; Fiscal Year: 2000
    ..abstract_text> ..
  24. PEG IFN VS ROFERON A FOR CHRONIC HEPATITIS C WITH CIRRHOSIS
    Paul Pockros; Fiscal Year: 1999
    ..abstract_text> ..
  25. PEGYLATED-IFN COMPARED TO STANDARD REGIMAN OF ROFERON -A FOR HEPATITIS C
    Luis Marsano; Fiscal Year: 2002
    ..abstract_text> ..
  26. A phase I/II trial of silymarin for chronic liver diseases
    Rajender Reddy; Fiscal Year: 2007
    ..This study will examine the safety and tolerability of various doses of milk thistle as well as start to explore its role in hepatitis C. ..
  27. HEPATITIS C VIRAL QUASISPECIES WITHIN THE LIVER
    Adrian Di Bisceglie; Fiscal Year: 2001
    ..These studies have great potential significance for understanding of viral clearance, development of persistent infection and for the development of a vaccine against HCV. ..
  28. HEPATITIS C VIRAL QUASISPECIES WITHIN THE LIVER
    Adrian Di Bisceglie; Fiscal Year: 2003
    ..These studies have great potential significance for understanding of viral clearance, development of persistent infection and for the development of a vaccine against HCV. ..
  29. Cell Culture System for Hepatitis C Virus Genotype 1a
    Adrian Di Bisceglie; Fiscal Year: 2008
    ..The availability of novel LRP and cloning technology will allow us to address this question in lieu of viral genetic heterogeneity. ..
  30. Management/Hepatitis C/HIV-infected and Uninfected IDU's
    Mark Sulkowski; Fiscal Year: 2006
    ..abstract_text> ..
  31. HCV Disease Management in HIV- HCV Coinfected IDUs
    MARK SEBASTIAN SULKOWSKI; Fiscal Year: 2010
    ..This research applies two highly innovative interventions, transient elastography and contingent behavioral reinforcement, to the evaluation and management of persons with HIV/HCV coinfection. ..
  32. Management/Hepatitis C/HIV-infected and Uninfected IDU's
    Mark Sulkowski; Fiscal Year: 2003
    ..abstract_text> ..
  33. Management/Hepatitis C/HIV-infected and Uninfected IDU's
    Mark Sulkowski; Fiscal Year: 2005
    ..abstract_text> ..
  34. HCV Disease Management in HIV- HCV Coinfected IDUs
    Mark Sulkowski; Fiscal Year: 2008
    ..This research applies two highly innovative interventions, transient elastography and contingent behavioral reinforcement, to the evaluation and management of persons with HIV/HCV coinfection. ..
  35. HEPATITIS C VIRAL QUASISPECIES WITHIN THE LIVER
    Adrian Di Bisceglie; Fiscal Year: 1999
    ..These studies have great potential significance for understanding of viral clearance, development of persistent infection and for the development of a vaccine against HCV. ..
  36. HEPATITIS C VIRAL QUASISPECIES WITHIN THE LIVER
    Adrian Di Bisceglie; Fiscal Year: 2000
    ..These studies have great potential significance for understanding of viral clearance, development of persistent infection and for the development of a vaccine against HCV. ..
  37. HCV Disease Management in HIV- HCV Coinfected IDUs
    Mark Sulkowski; Fiscal Year: 2009
    ..This research applies two highly innovative interventions, transient elastography and contingent behavioral reinforcement, to the evaluation and management of persons with HIV/HCV coinfection. ..
  38. Management/Hepatitis C/HIV-infected and Uninfected IDU's
    Mark Sulkowski; Fiscal Year: 2004
    ..abstract_text> ..
  39. Management/Hepatitis C/HIV-infected and Uninfected IDU's
    Mark Sulkowski; Fiscal Year: 2007
    ..abstract_text> ..
  40. HEPATITIS C VIRAL QUASISPECIES WITHIN THE LIVER
    Adrian Di Bisceglie; Fiscal Year: 2002
    ..These studies have great potential significance for understanding of viral clearance, development of persistent infection and for the development of a vaccine against HCV. ..
  41. HEPATITIS C VIRAL QUASISPECIES WITHIN THE LIVER
    Adrian Di Bisceglie; Fiscal Year: 2001
    ..These studies have great potential significance for understanding of viral clearance, development of persistent infection and for the development of a vaccine against HCV. ..
  42. Midwest Hepatitis B Consortium
    Adrian Di Bisceglie; Fiscal Year: 2008
    ..Finally, we propose studies on Health-Related Quality of Life (HRQOL) using the Hepatitis B Quality of Life instrument, version 1.0, HBQOL v1.0 developed and validated by Dr Fasiha Kanwal, consortium P.I. at the St. Louis VAMC. ..
  43. Hepatitis B Clinical Research Network
    Arun Sanyal; Fiscal Year: 2008
    ..Hypothesis 4: Insulin resistence and other features of the metabolic syndrome, which are common in African Americans, will reduce virologic response to peginterferon but not to a potent oral antiviral agent. ..
  44. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth Sherman; Fiscal Year: 2006
    ....
  45. Mentorship in Liver Disease
    Kenneth Sherman; Fiscal Year: 2007
    ..3. Review of the specific research activities funded by NIH and the pharmaceutical industry that serve as a structural framework for patient-oriented research ..
  46. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth Sherman; Fiscal Year: 2008
    ....
  47. Mentorship in Liver Disease
    Kenneth Sherman; Fiscal Year: 2008
    ..3. Review of the specific research activities funded by NIH and the pharmaceutical industry that serve as a structural framework for patient-oriented research ..
  48. Liver Disease and HIV
    Kenneth Sherman; Fiscal Year: 2008
    ..S. and international experts in the field to review the most current information and to develop research strategies that will reduce liver disease in these patients. ..
  49. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth Sherman; Fiscal Year: 2007
    ....
  50. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert Motzer; Fiscal Year: 2008
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  51. CLINICAL TRIALS AND MENTORING IN ONCOLOGY RESEARCH
    Robert Motzer; Fiscal Year: 2003
    ..One recently joined staff at MSKCC in the Genito-urinary Section. Mentoring of clinical trials is extended beyond fellowship to junior faculty members. ..
  52. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth E Sherman; Fiscal Year: 2010
    ....
  53. HCV Genomic Variability in HIV Infected Hemophiliacs
    Kenneth Sherman; Fiscal Year: 2001
    ..Treatment nonresponders will be followed in a prospective cohort study for up to 3 additional years so that the evolution of the virus, and its associated immune response in this group can be evaluated. ..
  54. Liver Disease and HIV
    Kenneth Sherman; Fiscal Year: 2006
    ..Particular attention will be played to development of new research concepts and establishment of collaborative associations. ..
  55. HCV Genomic Variability in HIV Infected Hemophiliacs
    Kenneth Sherman; Fiscal Year: 2004
    ..Treatment nonresponders will be followed in a prospective cohort study for up to 3 additional years so that the evolution of the virus, and its associated immune response in this group can be evaluated. ..
  56. U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
    Mamta Jain; Fiscal Year: 2004
    ..abstract_text> ..
  57. U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
    Mamta Jain; Fiscal Year: 2007
    ..abstract_text> ..
  58. U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
    Mamta Jain; Fiscal Year: 2008
    ..abstract_text> ..
  59. Molecular Basis of Interferon Response in HCV
    Mamta Jain; Fiscal Year: 2007
    ....
  60. Molecular Basis of Interferon Response in HCV
    Mamta Jain; Fiscal Year: 2008
    ....
  61. A Randomized Trial and Reduce to Disparity in Live Donor Kidney Transplantation
    James Rodrigue; Fiscal Year: 2007
    ..This proposal directly addresses three of the priority areas of HealthyPeople2010 (4-1, 4-5, 4-6). ..
  62. Pharmacogenetics of lipid response to estrogen therapy
    Jeanette McCarthy; Fiscal Year: 2009
    ..This may result in future clinically useful diagnostic tests that aid postmenopausal women in their decision whether to use estrogen therapy. ..
  63. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2009
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..
  64. Hepatitis B Clinical Research Network Clinical Center: Michigan-Hawaii consortium
    Anna Lok; Fiscal Year: 2008
    ..Clinical trials on other important topics such as treatment of patients in the immune tolerance phase and optimal management of patients with antiviral-resistant HBV are also discussed. ..
  65. A Randomized Trial and Reduce to Disparity in Live Donor Kidney Transplantation
    James Rodrigue; Fiscal Year: 2009
    ..This proposal directly addresses three of the priority areas of HealthyPeople2010 (4-1, 4-5, 4-6). ..
  66. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2008
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..
  67. Vulnerability to major depression: The role of delta sleep in patients receiving
    Francis E Lotrich; Fiscal Year: 2010
    ..This may be a common pathway for genes, stress, and inflammation to influence risk for depression. ..
  68. A Randomized Trial and Reduce to Disparity in Live Donor Kidney Transplantation
    James R Rodrigue; Fiscal Year: 2010
    ..This proposal directly addresses three of the priority areas of HealthyPeople2010 (4-1, 4-5, 4-6). ..
  69. Determinants of Medication Adherence in HIV-Infected Adults with Hypertension
    Jeffrey J Weiss; Fiscal Year: 2010
    ....
  70. A Randomized Trial and Reduce to Disparity in Live Donor Kidney Transplantation
    James R Rodrigue; Fiscal Year: 2010
    ..This proposal directly addresses three of the priority areas of HealthyPeople2010 (4-1, 4-5, 4-6). ..
  71. HIV and Hepatitis B Coinfection: Hepatitis B Genotype, Resistance and Outcomes
    Debika Bhattacharya; Fiscal Year: 2008
    ..If HBV virologic factors are associated with treatment outcomes in HIV/HBV coinfection, then identifying such factors may improve future diagnostic and therapeutic strategies in HIV/HBV co-infection. ..
  72. Directly Observed Hepatitis C Treatment in Methadone Clinics
    ALAIN LITWIN; Fiscal Year: 2008
    ..Findings from this project will be used to inform the development of a large randomized trial of the efficacy and cost-effectiveness of modified directly observed HCV care versus regular on-site care. ..
  73. EVALUATION OF A CONCEPTUAL MODEL OF ORGAN DONATION
    James Rodrigue; Fiscal Year: 2001
    ..abstract_text> ..
  74. EVALUATION OF A CONCEPTUAL MODEL OF ORGAN DONATION
    James Rodrigue; Fiscal Year: 2002
    ..abstract_text> ..
  75. Signaling Pathways in Hepatic Fibrogenesis
    Bruce Bacon; Fiscal Year: 2002
    ..Since activated HSC play a key role in hepatic fibrogenesis, these experiments will contribute to an improved understanding of the basic biochemical processes underlying hepatic fibrosis. ..
  76. Addiction Medicine Physicians and Care for Hepatitis C
    ALAIN LITWIN; Fiscal Year: 2003
    ..Data from this study will have relevance to both drug abuse treatment policy and clinical practice. ..
  77. Signaling Pathways in Hepatic Fibrogenesis
    Bruce Bacon; Fiscal Year: 2001
    ..Since activated HSC play a key role in hepatic fibrogenesis, these experiments will contribute to an improved understanding of the basic biochemical processes underlying hepatic fibrosis. ..
  78. VIRAHEP-C Clinical Center
    Anna Lok; Fiscal Year: 2005
    ..abstract_text> ..
  79. Signaling Pathways in Hepatic Fibrogenesis
    Bruce Bacon; Fiscal Year: 2005
    ..Since activated HSC play a key role in hepatic fibrogenesis, these experiments will contribute to an improved understanding of the basic biochemical processes underlying hepatic fibrosis. ..
  80. Adherence to HCV Treatment in HCV and HCV/HIV Patients
    Jeffrey Weiss; Fiscal Year: 2007
    ..The findings of this study will have important implications for the development of interventions to support and assist HCV and HCV/HIV patients in completing their course of PEG-IFN/RBV treatment. ..
  81. Basic & Clinical Research Training in Gastroenterology and Hepatology
    David Nelson; Fiscal Year: 2007
    ..Since 2002 the Gl Division has trained 21 Gl fellows, with 12 still in training. Of these 21 individuals, 2 are African American (10%), 2 are Hispanic (10%), and 7 are women (33%). ..
  82. Investigating structural-functional brain abnormalities in late-life depression
    Paul Holtzheimer; Fiscal Year: 2007
    ..It is hoped that a better understanding of the pathophysiology of late-life depression will lead to improvements in its diagnosis, prevention and treatment. ..
  83. Pharmacogenetics of lipid response to estrogen therapy
    Jeanette McCarthy; Fiscal Year: 2007
    ..This may result in future clinically useful diagnostic tests that aid postmenopausal women in their decision whether to use estrogen therapy. ..
  84. Biochemical Pharmacology of Anti-HIV Compounds
    Yung Chi Cheng; Fiscal Year: 2009
    ..4'-Ed4T could have the potential to replace AZT or D4T in anti-HIV HARRT and in overcoming drug resistant virus to other anti-HIV drugs at the relevant dosage without causing toxicity. ..
  85. BIOCHEMICAL PHARMACOLOGY OF ANTI-HIV-COMPOUNDS
    Yung Chi Cheng; Fiscal Year: 2002
    ..The information obtained will be useful for our understanding the differences in the effectiveness of anti-HIV-1 nucleoside analogs among different individuals and in a given patient through a period of treatment. ..
  86. BIOCHEMICAL ASPECTS OF CHEMOTHERAPY
    Yung Chi Cheng; Fiscal Year: 2007
    ....
  87. BIOCHEMICAL PHARMACOLOGY OF ANTI-HIV-COMPOUNDS
    Yung Chi Cheng; Fiscal Year: 2001
    ..The information obtained will be useful for our understanding the differences in the effectiveness of anti-HIV-1 nucleoside analogs among different individuals and in a given patient through a period of treatment. ..
  88. NUCLEOSIDE ANALOGS AS ANTICANCER COMPOUNDS
    Yung Chi Cheng; Fiscal Year: 2001
    ..abstract_text> ..
  89. NUCLEOSIDE ANALOGS AS ANTICANCER COMPOUNDS
    Yung Chi Cheng; Fiscal Year: 2006
    ..It should yield novel information for understanding the biochemical determinants of the action of L-OddC, the biochemistry of the enzymes studied and possible novel use of L-OddC for the treatment of solid tumor. ..
  90. NUCLEOSIDE ANALOGS AS ANTICANCER COMPOUNDS
    Yung Chi Cheng; Fiscal Year: 2002
    ..abstract_text> ..
  91. BIOCHEMICAL PHARMACOLOGY OF ANTI-HIV-COMPOUNDS
    Yung Chi Cheng; Fiscal Year: 2003
    ..The information obtained will be useful for our understanding the differences in the effectiveness of anti-HIV-1 nucleoside analogs among different individuals and in a given patient through a period of treatment. ..